The ratio of maximum percent tumour accumulations of the pretargeting agent and the radiolabelled effector is independent of tumour size

European Journal of Cancer

Volumn 45, Issue 17, 2009, Pages 3098-3103

  Liu, Guozheng ^a   Dou, Shuping ^a   Liang, Minmin ^a   Chen, Xiangji ^a   Rusckowski, Mary ^a   Hnatowich, Donald J ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

Effector; Optimisation; Pretargeting; Tumour accumulation; Tumour size

Indexed keywords

INDIUM CHLORIDE IN 111; MONOCLONAL ANTIBODY CC49; TECHNETIUM 99M;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY LABELING; ARTICLE; CONTROLLED STUDY; DRUG DISTRIBUTION; ISOTOPE LABELING; MOUSE; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; TARGET ORGAN; TUMOR LOCALIZATION; TUMOR MODEL; TUMOR VOLUME;

ANIMALS; ANTIBODIES, NEOPLASM; ANTINEOPLASTIC AGENTS; COLONIC NEOPLASMS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; INDIUM RADIOISOTOPES; MALE; MICE; MICE, NUDE; MORPHOLINES; NEOPLASM TRANSPLANTATION; RADIOPHARMACEUTICALS; TECHNETIUM COMPOUNDS; TISSUE DISTRIBUTION;

EID: 70350600582     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2009.09.007     Document Type: Article

References (17)

1. Moshakis V., McIlhinney R.A.J., Raghaven D., and Neville A.M. Localization of human tumour xenografts after i.v. administration of radiolabelled monoclonal antibodies. Br J Cancer 44 (1981) 91-99
2. Siegel J.A., Pawlyk D.A., Lee R.E., et al. Tumor, red marrow, and organ dosimetry for 131I-labeled anti-carcinoembryonic antigen monoclonal antibody. Cancer Res 50 (1990) 1039s-1042s
3. Sharkey R.M., Karacay H., Richel H., et al. Optimizing bispecific antibody pretargeting for use in radioimmunotherapy. Clin Cancer Res 9 10 Pt 2 (2003) 3897S-3913S
4. Liu G., Dou S., Pretorius P.H., et al. Pretargeting CWR22 prostate tumor in mice with MORF-B72.3 antibody and radiolabeled cMORF. Eur J Nucl Med Mol Imaging 35 (2008) 272-280
5. Krug L.M., Milton D.T., Jungbluth A.A., et al. Targeting Lewis Y (Le(y)) in small cell lung cancer with a humanized monoclonal antibody, hu3S193: a pilot trial testing two dose levels. J Thorac Oncol 2 (2007) 947-952
6. Czito B.G., Bendell J.C., Willett C.G., et al. Bevacizumab, oxaliplatin, and capecitabine with radiation therapy in rectal cancer: phase I trial results. Int J Radiat Oncol Biol Phys 68 (2007) 472-478
7. 90Y-DOTA-anti-CEA chimeric T84.66 (cT84.66) radioimmunotherapy in patients with metastatic CEA-producing malignancies. Cancer Biother Radiopharm 21 (2006) 88-100
8. Crane C.H., Ellis L.M., Abbruzzese J.L., et al. Phase I trial evaluating the safety of bevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer. J Clin Oncol 24 (2006) 1145-1151
9. Liu G., and Hnatowich D.J. A semiempirical model of tumor pretargeting. Bioconjug Chem 19 (2008) 2095-2104
10. Liu G, Dou S, Pretorius PH, et al. Tumor pretargeting in mice using phosphorodiamidate morpholino oligomer (MORF) conjugated CC49 antibody and radiolabeled complimentary MORF effector. Q J Nucl Med, in press.
11. Liu G., He J., Dou S., et al. Pretargeting in tumored mice with radiolabeled morpholino oligomer showing low kidney uptake. Eur J Nucl Med Mol Imaging 31 (2004) 417-424
12. Colcher D., Minelli M.F., Roselli M., et al. Radioimmunolocalization of human carcinoma xenografts with B72.3 second generation monoclonal antibodies. Cancer Res 48 (1988) 4597-4603
13. Davda J.P., Jain M., Batra S.K., Gwilt P.R., and Robinson D.H. A physiologically based pharmacokinetic (PBPK) model to characterize and predict the disposition of monoclonal antibody CC49 and its single chain Fv constructs. Int Immunopharmacol 8 (2008) 401-413
14. 111In-labeled HuCC49DeltaC(H)2 in BALB/c mice and athymic murine colon carcinoma xenograft. Cancer Biother Radiopharm 21 (2006) 106-116
15. Liu G., Dou S., He J., et al. Predicting the biodistribution of radiolabeled cMORF effector in MORF-pretargeted mice. Eur J Nucl Med Mol Imaging 34 (2007) 237-246
16. Liu G., Dou S., Rusckowski M., and Hnatowich D.J. An experimental and theoretical evaluation of the influence of pretargeting antibody on the tumor accumulation of effector. Mol Cancer Ther 7 (2008) 1025-1032
17. Liu G., He J., Dou S., et al. Further investigations of morpholino pretargeting in mice-establishing quantitative relations in tumor. Eur J Nucl Med Mol Imaging 32 (2005) 1115-1123